Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financi...(e results. Specifically the risks andunc...),Health

Date:5/7/2008

e results. Specifically, the risks and uncertainties include statements about future sales of Zevalin, reducing net operating expenses in 2008, the closing of an additional financing prior to July 4, 2008, the availability of adequate shares for future financings, and the development of OPAXIO, pixantrone, and brostallicin, which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO, pixantrone, and brostallicin in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, OPAXIO, pixantrone, and brostallicin, the Company's ability to continue to raise capital as needed to fund its operations, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors.htm '/>"/>

SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
5. Profarmas Gross Revenues Reached R$ 702.6 Million in the 1st Quarter 2008, a 26.5% Growth Over the Same Period Last Year
6. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. MEDRAD(R) Revenues Grow 10 Percent in 2007
9. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
10. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
11. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent